動脈硬化性心血管疾患（ASCVD）の二次予防を目的とした、LDLコレステロール（LDL-C）の管理に関するコンセンサス・オピニオンが正式発表された。日本動脈硬化学会の「ASCVD患者の脂質管理に関するワーキンググループ」が編集作業を進めていたもので、2025年 ...

Low-Density Lipoprotein Cholesterol (LDL-C), often labeled as “bad cholesterol,” is increasingly being recognized not just as a marker, but as the primary causal factor in the development of ...

リポ蛋白（a）[Lp(a)]とLDLコレステロール（LDL-C）は、どちらも動脈硬化性心血管疾患（ASCVD）の独立した相加的な危険因子であり、スタチンの投与によりLDL-Cが大幅に低下してもLp(a)が高値ならASCVDリスクは残存することが、スタチンを用いた6件の大規模 ...

Such a puzzle since the patient had neither CVD risk factors nor atherosclerotic changes ...

Having “normal” cholesterol levels is often seen as a green signal for good heart health, but growing evidence suggests otherwise. The long-held belief that normal LDL automatically means low cardiac ...

Q: How much does a normal or high HDL cholesterol protect you from the adverse health effects of a high LDL cholesterol? A: Lowering elevated levels of low-density lipoprotein (LDL), or “bad” ...

PITTSBURGH, Oct. 30, 2025 – An international team led by a University of Pittsburgh School of Medicine scientist has created a first-of-its-kind resource to identify those with a genetic risk for ...